Sifi Launches EpiColin Glaucoma Supplement in Italy

Sifi announced the launch in Italy of EpiColin, a food supplement dedicated to patients suffering from glaucoma. 

Following Amiriox and Ecbirio, IOP drugs fully reimbursed by the Italian NHS, EpiColin is the third innovation in the glaucoma therapeutic area introduced by Sifi in the second half of 2022.

EpiColin is a food supplement based on plant extracts of Coleus forskohlii and green tea, with citicoline, homotaurine, vitamins B and vitamin E.

“It is common knowledge today that eye pressure is not the only risk factor for glaucoma progression,” Dr. Matteo Sacchi, Head of the Glaucoma Center of the University Ophthalmology Clinic, San Giuseppe Hospital - IRCCS MultiMedica, Milan, said in a company news release. "Growing attention is now also focused on aspects such as oxidative stress, neuroinflammation and mitochondrial dysfunction, confirming the importance of a synergistic therapeutic approach that includes a short-term and long-term perspective view of the patient.” 

EpiColin’s therapeutic supplementation has been designed to produce a significant neuroprotective and antioxidant effect due to the combined action of the individual well-known and reliable components, complementing intraocular pressure therapy, according to Sifi. The neuroprotective effect of nutraceuticals has been demonstrated both in preclinical in vitro and in vivo studies, and in clinical studies[6]. 

References

6. Sim RH, et al. Nutrients. 2022 Jan 26;14(3):534.